Journal article

A new classification and class 1 evidence transform clinical practice in epilepsy

Ingrid E Scheffer

The Lancet Neurology | ELSEVIER SCIENCE INC | Published : 2018

University of Melbourne Researchers


Funding Acknowledgements

I received grants from the Australian National Health and Medical Research Council and the US National Institutes of Health, speaker fees from UCB, GlaxoSmithKline, Sanofi, Eisai, and Zogenix, participated in an epilepsy consortium for GW Pharmaceuticals, I am the chair of a scientific advisory board for BioMarin and Nutricia; I receive royalties for a patent for diagnostic and therapeutic methods for epilepsy and mental retardation limited to females (WO/2009/086591), and hold a license for a patent for methods of treatment and diagnosis of epilepsy by detecting mutations in the SCN1A gene (WO/2006/133508).